Thomas Tan joins Sound Bioventures

Today it was announced that Thomas Tan has joined the Sound Bioventures team as a Principal. Thomas will identify new investment opportunities, conduct scientific and commercial due diligence, and participate in board work.

Prior to joining Sound Bioventures, Thomas was a senior principal at Lundbeckfonden Ventures, were he identified and managed investments, and was a board member at Atox Bio and VarmX. Prior to his position at Lundbeckfonden Ventures, he worked as a strategy consultant at LSD, Huron and Deallus advising biotech and pharma on portfolio strategy, product positioning and pricing. Before that Thomas started his own biotech company in Cambridge, UK.

Thomas received his postdoctoral training at University of Cambridge, UK after earning his D. Phil. in Medical Sciences from University of Oxford, UK, and his M.Sc. in Biochemistry from University of Copenhagen, DK.

Thomas will be based in the Copenhagen, Denmark, office.

ARTHEx Biotech Receives IND Clearance from FDA to Initiate the Phase I-IIa ArthemiR™ Trial of ATX-01 for Myotonic Dystrophy Type 1 (DM1)

-ATX-01 is the industry’s first microRNA therapeutic to be evaluated for DM1 and the first program from ARTHEX’s pipeline to enter the clinic – -First patient expected to be enrolled in Q2 2024- Valencia, Spain, February 28th, 2024 – ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the m ...

Subscribe

* indicates required